Intermittent endocrine therapy for advanced prostate cancer

Cancer

Volumn 58, Issue 11, 1986, Pages 2546-2550

  Klotz, Laurence H ^a,b   Herr, Harry W ^a   Morse, Michael J ^a   Whitmore, Willet F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLSTILBESTROL; FLUTAMIDE;

ADVERSE DRUG REACTION; BONE; BONE PAIN; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DRUG DOSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG THERAPY; ENDOCRINE SYSTEM; HORMONAL THERAPY; HUMAN; IMPOTENCE; MALE GENITAL SYSTEM; ORAL DRUG ADMINISTRATION; PERIPHERAL VASCULAR SYSTEM; PRIORITY JOURNAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; THERAPY;

AGED; BONE NEOPLASMS; DIETHYLSTILBESTROL; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGE; PALLIATIVE CARE; PILOT PROJECTS; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 0022997273     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19861201)58:11<2546::AID-CNCR2820581131>3.0.CO;2-N     Document Type: Article

References (15)

1. Studies of prostatic cancer: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
2. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland
3. Survival following castration for prostatic cancer
4. Endocrine control of prostatic carcinoma: Clinical and statistical survey of 1818 cases
5. Prostatic carcinoma: A follow‐up of 795 patients treated prior to the endocrine era and a comparison of survival rates between these and patients treated by endocrine therapy
6. Treatment and survival of patients with cancer of the prostate
7. Therapy with orchiectomy or estrogens or both
8. The VACURG studies of carcinoma of the prostate: A review
9. Prostate tumor biology and cell kinetics: Theory
10. Mechanisms for and implications of the development of heterogeneity of androgen sensitivity in prostate cancer
11. Optimal testosterone concentration for the treatment of prostatic cancer
12. Hormonal control of growth and progression in tumors of Nb rats and a theory of action
13. New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens
14. Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone‐releasing hormone agonists in the treatment of prostate cancer
15. Comparison between continuous and intermittent administration of Estracyt in the treatment of carcinoma of the prostate